Amphastar Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: AMPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amphastar Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Amphastar Pharmaceuticals generated $51.3 million of operating cash flow and spent $8.6 million on capital expenditures. That left free cash flow of $42.7 million, a free-cash-flow margin of 23.2% of revenue. Free cash flow was up 70.7% from the prior year's $25.0 million.
Amphastar Pharmaceuticals returned $45.2 million to shareholders through share repurchases, equal to 106% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Amphastar Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 30.35M | 6.42M | 24.43M | 17.35M | 31.03M | 25.29M | 37.96M | 40.43M | 37.95M | 43.18M | 36.17M | 49.22M |
| Net Income growth (YoY) | -2.20% | -74.61% | -35.65% | -57.09% | -18.23% | -41.44% | +4.97% | -17.86% | +45.26% | +65.86% | +6.65% | +210.08% |
| Depreciation & Amortization | 14.31M | 8.08M | 8.07M | 14.13M | 14.62M | 7.37M | 7.26M | 13.40M | 13.15M | 9.66M | 9.66M | 9.62M |
| Stock-Based Compensation | 7.09M | 9.27M | 6.21M | 6.30M | 6.38M | 8.39M | 5.63M | 5.60M | 5.78M | 7.36M | 4.62M | 4.64M |
| Change in Working Capital | -7.48M | 8.98M | -20.57M | 9.47M | -1.98M | -22.43M | -19.69M | -1.45M | 13.81M | -10.31M | 2.68M | -18.05M |
| Operating Cash Flow | 51.32M | 47.84M | 32.86M | 52.58M | 35.59M | 35.08M | 29.02M | 59.96M | 69.11M | 55.29M | 23.86M | 64.33M |
| Capital Expenditures | -8.59M | -9.51M | -8.27M | -5.35M | -10.56M | -10.70M | -12.41M | -13.79M | -6.04M | -8.79M | -9.44M | -10.19M |
| Investing Cash Flow | 44.87M | -16.73M | -60.57M | -19.62M | -625.00K | 10.48M | -35.68M | -34.59M | -69.90M | 15.24M | -103.05M | -31.15M |
| Share Repurchases | -45.21M | -29.49M | -20.52M | -4.85M | -39.22M | -11.00M | -42.00M | -34.96M | — | — | 0 | -50.00M |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | 345.00M |
| Debt Repaid | -47.00K | -29.00K | -104.00K | -44.00K | -37.00K | -38.00K | -115.00K | -41.00K | -8.01M | -98.00K | -50.15M | -200.07M |
| Financing Cash Flow | -43.53M | -30.21M | -18.37M | -4.35M | -30.20M | -14.50M | -33.84M | -22.82M | -10.72M | -13.58M | -47.08M | 86.61M |
| Net Change in Cash | 52.67M | 762.00K | -46.09M | 28.58M | 4.91M | 31.17M | -40.51M | 2.50M | -11.53M | 56.85M | -126.51M | 119.76M |
| Free Cash Flow | 42.73M | 38.33M | 24.59M | 47.23M | 25.03M | 24.38M | 16.61M | 46.17M | 63.06M | 46.50M | 14.42M | 54.14M |
This table shows 12 quarterly periods of Amphastar Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AMPH's reporting calendar. What is a cash flow statement?